Salvage_therapy_with_high-dose_chemotherapy_and_autologous_bone_marrow_support_in_the_treatment_of_primary_nonseminomatous_mediastinal_germ_cell_tumors._The_authors_reported_their_experience_with_the_use_of_high-dose_chemotherapy_and_autologous_bone_marrow_rescue_(ABMR)_as_salvage_therapy_in_the_treatment_of_patients_with_recurrent_and_refractory_primary_nonseminomatous_mediastinal_germ_cell_tumors_(PMGCT)._Since_1987,_the_authors_have_treated_12_patients_with_PMGCT_with_high-dose_carboplatin_(1500_mg/m2_to_1800_mg/m2)_and_etoposide_(1200_mg/m2_to_1350_mg/m2)_(in_two_patients_ifosfamide_10_g/m2_was_added)_with_ABMR._Patients_were_either_in_second_relapse_or_cisplatin_refractory_(progression_within_4_weeks_of_last_cisplatin_dosing)._They_had_received_a_median_of_two_prior_chemotherapy_regimens_(range,_one_to_three),_all_had_had_prior_cisplatin_therapy,_and_most_had_failed_ifosfamide-based_therapy._Six_patients_were_cisplatin_refractory_and_of_these_only_one_achieved_a_partial_response_(PR)_that_was_of_short_duration._It_was_planned_that_all_patients_would_undergo_two_rounds_of_therapy;_however,_only_5_of_12_patients_received_two_courses._The_remainder_had_only_one_round_of_therapy_either_because_of_inadequate_response_(three_patients)_or_excessive_toxicity_(four_patients)._There_were_four_patients_who_died_in_the_peritransplant_period_due_to_sepsis_(two_patients)_or_bleeding_(two_patients)._The_median_survival_of_the_group_was_107_days_(range,_14_days_to_347_days)._No_patient_achieved_a_complete_remission,_but_there_were_six_partial_remissions,_four_with_stable_disease,_and_two_with_progressive_disease._The_use_of_high-dose_carboplatin_and_etoposide_with_or_without_ifosfamide_and_ABMR_was_not_effective_in_the_treatment_of_this_group_of_patients_with_PMGCT_who_were_in_second_relapse_or_cisplatin_refractory.